Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ian Hirsch"'
Publikováno v:
Advances in Therapy
Introduction For patients with eosinophilic asthma with allergic characteristics, understanding the key drivers of exacerbations is important to identify optimal treatment strategies. Benralizumab is an interleukin-5 receptor alpha–directed cytolyt
Publikováno v:
TP10. TP010 CLINICAL AND POPULATION-LEVEL STUDIES OF ASTHMA.
Autor:
Ian D. Pavord, Malin Fagerås, Mitchell Goldman, J. Mark FitzGerald, Gene L. Colice, Guy Brusselle, Matthew Keith, Ian Hirsch, Esther Garcia Gil, Monica Kraft
Publikováno v:
EUROPEAN RESPIRATORY JOURNAL
BackgroundGreater precision in asthma exacerbation risk prediction may improve outcomes. We sought to identify clinical characteristics and biomarkers associated with elevated exacerbation risk in patients with severe, uncontrolled asthma.MethodsData
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d75a5997d3a606a74141bc00eafa5d19
https://biblio.ugent.be/publication/8714420
https://biblio.ugent.be/publication/8714420
Publikováno v:
Annals of Allergy, Asthma & Immunology. 121:S39-S40
Introduction Greater clarity is needed on peripheral blood eosinophil counts (BEC) associated with events such as exacerbations or responsiveness to biologics in severe asthma. Inclusion criteria and prespecified analyses on peripheral BECs vary betw
Autor:
J. Mark FitzGerald, Andrew Menzies-Gow, Paul Newbold, Paul Metcalfe, James Zangrilli, Ian Hirsch, Mitchell Goldman, Eugene R. Bleecker
Publikováno v:
The Lancet. Respiratory medicine. 6(1)
Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor α monoclonal antibody that has been shown to significantly reduce asthma exacerbations and improve lung function for patients with severe, uncontrolled asthma. We further explored the
Publikováno v:
Current medical research and opinion. 33(9)
Objective: Benralizumab, an anti-eosinophilic monoclonal antibody, in combination with high-dosage inhaled corticosteroids and long-acting β2-agonists (ICS/LABA), significantly reduced asthma exacerbations, improved lung function, and reduced sympto
Publikováno v:
Pneumologie. 72:S13-S13
Publikováno v:
Annals of Allergy, Asthma & Immunology. 119:S56